A receptor-binding radiopharmaceutical for imaging of traumatic brain injury in a rodent model: [
Blood brain barrier
Fluorescence imaging
Microglial cells
Tilmanocept
Traumatic brain injury
cd206
Journal
Nuclear medicine and biology
ISSN: 1872-9614
Titre abrégé: Nucl Med Biol
Pays: United States
ID NLM: 9304420
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
08
01
2020
revised:
19
02
2020
accepted:
24
02
2020
pubmed:
15
3
2020
medline:
5
10
2021
entrez:
15
3
2020
Statut:
ppublish
Résumé
Blood-brain barrier (BBB) disruption and subsequent neuro-inflammation occur following traumatic brain injury (TBI), resulting in a spectrum of human nervous system disorders. [ Age-matched mice were divided into three groups: 5-days post TBI (n = 4), and 5-days post sham (n = 4), and naïve controls (n = 4). IRDye800CW-labeled [ In vivo nuclear imaging, ex vivo fluorescence imaging, ex vivo gamma well counting, and histo-microscopy demonstrated enhanced tilmanocept uptake in the TBI region. The normalized [ [
Identifiants
pubmed: 32169304
pii: S0969-8051(20)30003-2
doi: 10.1016/j.nucmedbio.2020.02.013
pii:
doi:
Substances chimiques
Dextrans
0
Mannans
0
Radiopharmaceuticals
0
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
0
Technetium Tc 99m Pentetate
VW78417PU1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
107-114Subventions
Organisme : NCI NIH HHS
ID : P50 CA128346
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest David Vera is the inventor of Tilmanocept. The remaining authors declare that they have no conflict of interest.